An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Nivolumab (Primary) ; Cetuximab; Docetaxel; Methotrexate
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 141
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 12 Oct 2017 Results assessing association of Health-Related Quality of Life (Hrqol) and Healthcare Resource Utilization (Hcru) presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 12 Oct 2017 Results assessing quality-adjusted time without symptoms of disease and toxicity (Q-Twist) analysis comparing nivolumab and therapy of investigator's choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top